Intra-Cellular Therapies Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
131.75
0.06
(0.05%)
Volume:
1,868,089
52 week range:
64.09 - 131.79
Market Cap:
14.009B
Company Description:
Intra-Cellular Therapies, Inc. develops novel drugs for the treatment of neuropsychiatric and neurologic diseases. The company offers CAPLYTA for schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for bipolar depression, as well as to treat autism spectrum disorder.